艾伏尼布方案治疗IDH1突变急性髓系白血病的真实世界疗效与安全性
该回顾性研究分析16例接受艾伏尼布(IVO)方案治疗的IDH1突变急性髓系白血病(AML)患者,覆盖诱导、巩固、挽救及维持各阶段。结果显示含IVO方案在各阶段均具良好疗效,≥3级不良事件以血细胞减少为主,安全性可控。
要点
- 含IVO方案在诱导、巩固、挽救及维持各阶段均观察到完全缓解或持续缓解。
- 常见≥3级不良事件为中性粒细胞减少、贫血和血小板减少。
- 分化综合征和QT间期延长发生率均为12.5%,无治疗相关死亡。
核心结论
- 含IVO方案用于IDH1突变AML各阶段治疗显示良好疗效与安全性,值得临床进一步推广运用。
研究设计与样本
- 回顾性分析2021年9月至2025年5月南方医科大学南方医院收治的16例接受IVO治疗的IDH1突变AML患者临床资料。
- 患者中位年龄57(25~80)岁,男7例,女9例。
主要发现
- 5例(31.2%)接受VA联合IVO诱导治疗,3例获完全缓解(CR),其中2例MRD转阴并伴IDH1 dPCR阴性。
- 2例(12.5%)接受VA+IVO巩固治疗,均维持CR,其中1例MRD阴性且伴IDH1 dPCR阴性。
- 4例(25.0%)复发/难治患者接受维奈克拉+去甲基化药物+IVO(3例)或IVO单药(1例)挽救治疗,均获CR,其中3例MRD阴性,1例伴IDH1 dPCR阴性。
- 5例(31.2%)接受IVO维持治疗,持续缓解时间(DOR)>12个月。
- 主要≥3级不良事件为中性粒细胞减少(56.3%)、贫血(43.8%)及血小板减少(37.5%),IVO相关不良反应包括分化综合征(12.5%)及QT间期延长(12.5%),无患者死于治疗相关并发症。
临床怎么用
- 对于IDH1突变AML患者,可考虑在诱导、巩固、挽救及维持各阶段应用含IVO方案。
- 治疗期间需监测分化综合征和QT间期延长等IVO相关不良反应。
局限性
- 本研究为单中心回顾性分析,样本量仅16例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To evaluate the real-world application of ivosidenib (IVO) in patients with IDH1-mutated acute myeloid leukemia (AML), as well as its efficacy and safety. We retrospectively analyzed clinical data from 16 patients with IDH1-mutated AML who received IVO-based therapy at Nanfang Hospital between September 2021 and May 2025. The median age was 57 years (range, 25 - 80 years), with 7 males and 9 females. Six patients (37.5%) had an Eastern Cooperative Oncology Group performance status of 3 - 4, and 14 patients (87.5%) were classified as intermediate- or high-risk according to the European LeukemiaNet criteria. Among 5 patients (31.2%) receiving venetoclax (VEN) plus azacitidine (AZA) combined with IVO for induction, 3 achieved complete remission (CR), including 2 with measurable residual disease (MRD) -negative and IDH1 dPCR-negative status. Two patients (12.5%) received VA plus IVO for consolidation; both maintained CR, with 1 achieving MRD-negative and IDH1 dPCR-negative status. Four relapsed or refractory patients (25.0%) received VEN plus hypomethylating agents (HMA) combined with IVO (n=3) or IVO alone (n=1) for salvage therapy. All patients achieved CR, of whom 3 obtained MRD-negative results, and 1 was IDH1 dPCR-negative. Five patients (31.2%) received IVO as maintenance therapy, with a duration of response exceeding 12 months. The most common grade ≥3 adverse events were neutropenia (56.3%), anemia (43.8%), and thrombocytopenia (37.5%). IVO-related adverse events included differentiation syndrome (12.5%) and QT interval prolongation (12.5%), and no treatment-related deaths were observed. IVO-based regimens demonstrated favorable efficacy and a manageable safety profile across all treatment phases in patients with IDH1-mutated AML, supporting their broader clinical application. 为评估真实世界中艾伏尼布(Ivosidenib,IVO)治疗IDH1突变急性髓系白血病(AML)患者的疗效和安全性,回顾性分析2021年9月至2025年5月南方医科大学南方医院收治的16例接受IVO治疗的IDH1突变AML患者临床资料。患者中位年龄57(25~80)岁,男7例,女9例,6例(37.5%)患者的ECOG评分为3~4分。14例(87.5%)为欧洲白血病网(ELN)危险分层中高危组。5例(31.2%)接受VA(维奈克拉+阿扎胞苷)联合IVO诱导治疗,3例获完全缓解(CR),其中2例可检测残留病(MRD)转阴并伴有IDH1数字PCR(dPCR)阴性;2例(12.5%)接受VA+IVO巩固治疗,均维持CR,其中1例MRD阴性且伴IDH1 dPCR阴性;4例(25.0%)复发/难治患者接受维奈克拉+去甲基化药物+IVO (3例)或IVO单药(1例)挽救治疗,均获CR,其中3例MRD阴性,1例伴IDH1 dPCR阴性;5例(31.2%)接受IVO维持治疗,持续缓解时间(DOR)>12个月。主要≥3级不良事件为中性粒细胞减少(56.3%)、贫血(43.8%)及血小板减少(37.5%),IVO相关不良反应包括分化综合征(12.5%)及QT间期延长(12.5%),无患者死于治疗相关并发症。提示含IVO方案用于IDH1突变AML各阶段治疗显示良好疗效与安全性,值得临床进一步推广运用。.
引用
- Chen DD, Xu JC, Yin Z, et al. [Efficacy and safety of ivosidenib-based therapy in 16 patients with IDH1-mutated acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42706177. doi:10.3760/cma.j.cn121090-20251125-00546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。